



## Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-02102-9>.  
Published online 15 December 2022.

<https://doi.org/10.1038/s41591-023-02302-x>

Published online: 17 March 2023

Orly Vardeny<sup>1</sup>, James C. Fang, Akshay S. Desai, Pardeep S. Jhund<sup>2</sup>, Brian Claggett, Muthiah Vaduganathan, Rudolf A. de Boer<sup>3</sup>, Adrian F. Hernandez, Carolyn S. P. Lam<sup>4</sup>, Silvio E. Inzucchi, Felipe A. Martinez, Mikhail N. Kosiborod<sup>5</sup>, David DeMets, Eileen O'Meara, Shelley Zieroth<sup>6</sup>, Josep Comin-Colet<sup>7</sup>, Jaroslaw Drozd<sup>8</sup>, Chern-En Chiang, Masafumi Kitakaze<sup>9</sup>, Magnus Petersson<sup>10</sup>, Daniel Lindholm<sup>11</sup>, Anna Maria Langkilde, John J. V. McMurray<sup>12</sup> & Scott D. Solomon<sup>13</sup>

In the version of this article initially published, there was an error in the abstract, where in the sentence now reading, in part, “In participants with HFimpEF... first worsening heart failure events (HR = 0.84),” the hazard ratio originally read “0.78,” while in the second paragraph of the “Outcomes by HFimpEF status” Results subsection, in the sentence now reading, in part, “The effect of dapagliflozin on HF outcomes was also similar in those with HFimpEF (HR = 0.84, 95% CI = 0.61–1.14) and those with LVEF consistently over 40% (HR = 0.78),” the hazard ratio values were mistakenly interchanged. The values have been updated in the HTML and PDF versions of the article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

## Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-02183-6>.  
Published online 6 February 2023.

<https://doi.org/10.1038/s41591-023-02308-5>

Published online: 20 March 2023

Sigrún Thorsteinsdóttir<sup>1</sup>, Gauti K. Gíslason<sup>2</sup>, Thor Aspelund<sup>3</sup>, Sæmundur Rögnvaldsson, Jón Þórir Óskarsson<sup>4</sup>, Guðrún Á Sigurðardóttir, Ásdís R. Þórðardóttir, Brynjar Viðarsson, Páll T. Öundurson, Bjarni A. Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Elías Eypórsson, Ásbjörn Jónsson, Oscar Berlanga, Malin Hultcrantz, Brian G. M. Durie, Thorvardur J. Löve, Stephen Harding, Ola Landgren<sup>5</sup> & Sigurður Y. Kristinsson

In the version of this article initially published, the name of Malin Hultcrantz was misspelled (Hulcrantz) and has now been corrected in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023